Author： Pettit G.R. Moser B.R. Boyd1 M.R. Schmidt J.M. Pettit R.K. Chapuis J-C.
Publisher： Cognizant Communication Corporation
ISSN： 1460-2148
Source： Anti-Cancer Drug Design, Vol.16, Iss.4, 2001-08, pp. : 185-193
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The original synthesis of combretastatin A-2 (1a) was modified to provide an efficient scale-up procedure for obtaining this antineoplastic stilbene. Subsequent conversion to a useful prodrug was accomplished by phosphorylation employing in situ formation of dibenzylchlorophosphite followed by cleavage of the benzyl ester protective groups with bromotrimethylsilane to afford the phosphoric acid intermediate 11. The latter was immediately treated with sodium methoxide to complete a practical route to the disodium phosphate prodrug (2a). The phosphoric acid precursor (11) of phosphate 2a was employed in a parallel series of reactions to produce a selection of metal and ammonium cation prodrug candidates. Each of the phosphate salts (2aq) was evaluated with respect to relative solubility behavior, cancer cell growth inhibition and antimicrobial activity.
Related content
Access to resources
Recommend
By He L. Chang H.-X. Chou T.-C. Savaraj N. Cheng C.C.
European Journal of Medicinal Chemistry, Vol. 38, Iss. 1, 2003-01 ,pp. :